
Biosystem Development
802 Deming Way, Suite 172, Madison, WI, 53717, United States
Overview
BioSystem Development creates, manufactures and markets the AssayMAP microchromatography technology, a platform based on disposable micro‑chromatography cartridges and automation. The AssayMAP platform enables high-throughput solutions for bioprocess development, biomarkers and general life‑science research that reduce development time and increase efficiency. The company markets patented AssayMAP® technology and recently launched the fully automated AssayMAP Bravo® system, co-developed with Agilent Technologies. BioSystem Development intends to use new funding to scale up manufacturing capabilities, accelerate time to market for new products and support pipeline expansion. The company said demand from strategic partners has increased following the Bravo launch. BioSystem Development was established in 2002 and is based in Madison, Wis. BioSystem Development, founded in 2002 and based in Madison, Wis., designs, manufactures and markets tools and products to meet the needs of pharmaceutical development. Its core product is the AssayMAP platform, which is based on disposable micro‑chromatography cartridges and automation. The AssayMAP platform enables high‑throughput solutions for bioprocess development, biomarkers and general life‑science research. In November 2010 the company completed a $978,000 funding round. The capital will enable the company to expand its manufacturing infrastructure and to launch new AssayMAP products into the biopharmaceutical development market. Founder and CEO Scott Fulton said the funding provides the means to respond to growing market interest and launch several disruptive AssayMAP products. BioSystem Development, LLC develops and manufactures the AssayMAP™ Bioanalysis System, an open platform intended to improve analytical workflows for biopharmaceutical process development. The company completed an over $1.4M investment round composed of capital equipment and funding. Two strategic manufacturing partners, All Metal Stamping and Orbital Biosciences, contributed $350,000 in tooling and manufacturing infrastructure. The remaining just over $1.0M came from current investors and new contributors, including groups from Marshfield Investment Partners, Silicon Pastures and the Chippewa Valley Angel Investors Network. Management said the funding will support formalizing key strategic technology and commercial partnerships. The company also plans to use proceeds to launch several new AssayMAP products.
- Total raised
- $3M
- Funding rounds
- 4
- Latest round
- Equity
- Latest activity
- Jul 2011
Industries
- Biotechnology
- Lending
- Manufacturing
Recent funding
Equity
Jul 2011
$1M
Equity
Oct 2010
$1M
Equity
Nov 2009
$1M
Team
No current team members are available.